Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The schizophrenia market was valued at USD 8.23 Billion in 2025. It is poised to grow at a CAGR of 5.80% during the forecast period of 2026-2035, and reach USD 14.46 Billion by 2035. The market growth is driven by the rising prevalence of schizophrenia, increasing awareness, improved diagnosis rates, and growing adoption of advanced antipsychotic therapies, including long-acting injectable formulations globally.
Latest News on the Schizophrenia Market (2026)
- In February 2026, the FDA approved Bysanti (milsaperidone) for schizophrenia, targeting dopamine and serotonin receptors with improved symptom control and planned commercialization.
- In November 2025, the FDA expanded Caplyta approval for depression adjunct use alongside schizophrenia, improving symptoms without significant metabolic side effects.
- In December 2025, Newron initiated ENIGMA-TRS 2 Phase III global trial in the US evaluating evenamide as add-on therapy for treatment-resistant schizophrenia.
Key Market Trends and Insights
- By drug class, second-generation antipsychotics are likely to hold over 69% of the market share in the historical period and are expected to dominate the schizophrenia market.
- By distribution channel, retail pharmacies are expected to account for above 54% of the market size in the historical period and are expected to lead the market.
- By region, North America is anticipated to hold 45.05% revenue share in the historical period and is expected to dominate the market.
Market Size and Forecast
- Market Size (2025): USD 8.23 Billion
- Projected Market Size (2035): USD 14.46 Billion
- CAGR (2026-2035): 5.80%
2025
Base Year
2019-2025
Historical Period
2026-2035
Forecast Period
Compound Annual Growth Rate
5.8%
Value in USD Billion
2026-2035
*this image is indicative*
Read more about this report - Request a Free Sample
Schizophrenia Market Overview
The market is growing due to increasing disease prevalence, improved diagnosis, and advancements in long-acting formulations. Development of novel therapies targeting dopamine D2 receptor pathways is enhancing treatment outcomes. Rising use of atypical antipsychotic and clozapine is supporting management of treatment-resistant schizophrenia, while focus on negative symptoms and cognitive impairment schizophrenia is driving innovation in therapeutic approaches globally. The market reached a value of approximately USD 8.23 Billion in 2025.
Schizophrenia Market Growth Drivers
Expanding Treatment Scope of Multimodal Antipsychotic Therapies Accelerating the Market Value
Rising prevalence of schizophrenia, increasing comorbid depression cases, and demand for safer long-term psychiatric therapies are supporting market growth. Focus on multifunctional drugs is improving adherence and outcomes. For instance, in November 2025, the FDA expanded approval of Johnson & Johnson’s Caplyta (lumateperone) for adjunct major depressive disorder treatment alongside schizophrenia, showing improved symptoms without significant metabolic side effects such as weight gain.
Schizophrenia Market Trends
Key trends shaping the market include development of novel antipsychotics, digital psychiatry adoption, and increasing focus on personalized schizophrenia treatment approaches.
Breakthrough Neurotransmitter-Targeting Therapies to Propel the Market Expansion
Innovation in non-dopamine mechanisms, demand for better symptom control, and regulatory support for novel psychiatric drugs are reshaping treatment development. The market is shifting toward next-generation therapies with improved safety and efficacy. For instance, in February 2026, the FDA approved Vanda Pharmaceuticals’ Bysanti (milsaperidone) for schizophrenia, targeting dopamine and serotonin receptors, with clinical data showing improved symptom control and planned late-2026 commercialization.
Schizophrenia Market Segmentation
Market Breakup by Type
- Paranoid Schizophrenia
- Hebephrenic Schizophrenia
- Catatonic Schizophrenia
- Undifferentiated Schizophrenia
Market Breakup by Drug Class
- First Generation Antipsychotics
- Chlorpromazine
- Fluphenazine
- Haloperidol
- Perphenazine
- Others
- Second Generation Antipsychotics
- Aripiprazole
- Cariprazine
- Brexpiprazole
- Aripiprazole Lauroxil
- Others
- Third-Generation/Novel Antipsychotics
- Lumateperone
- Pimavanserin-based Therapies
- Long-Acting Injectable Antipsychotics
- Others
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Homecare Settings
- Others
Market Breakup by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
Market Breakup by Country
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Read more about this report - Request a Free Sample
Schizophrenia Market Share
Second-Generation Antipsychotics Likely to Lead the Market Segment by Drug Class
Second-generation antipsychotics held about 69% of the market share in the historical period, indicating strong preference for improved safety and efficacy profiles. The segment is likely to dominate due to sustained clinical adoption and better tolerability compared to first-generation options. Increasing use of atypical antipsychotic therapies continues to support its leading position in schizophrenia treatment approaches globally.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Read more about this report - Request a Free Sample
Schizophrenia Market Analysis by Region
North America is expected to lead the market with nearly 45% revenue share in the historical period, reflecting strong healthcare infrastructure and high diagnosis rates. The region is likely to dominate the market due to advanced treatment access and robust mental health awareness. Expanding utilization of long-acting injectable antipsychotic therapies further supports improved adherence and strengthens regional leadership in schizophrenia management across healthcare systems.
Leading Players in the Schizophrenia Market
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Bristol-Myers Squibb Company
Headquartered in New York, USA, and founded in 1887, Bristol-Myers Squibb Company is a global biopharmaceutical leader focused on oncology, immunology, and neuroscience. Its schizophrenia portfolio includes Abilify Maintena and collaboration products like Rexulti for maintenance therapy. For instance, ongoing CNS portfolio expansion supports improved outcomes in long-acting injectable antipsychotic treatments.
AstraZeneca PLC
AstraZeneca PLC, headquartered in Cambridge, United Kingdom, and established in 1999, is a global pharmaceutical company with strong CNS and mental health portfolios. Its schizophrenia-related therapy includes Seroquel (quetiapine), used to manage psychotic symptoms and bipolar disorder. The company continues to strengthen neuroscience research supporting atypical antipsychotic development for improved patient quality of life globally.
Eli Lilly and Company
Eli Lilly and Company, headquartered in Indianapolis, USA, and founded in 1876, is a leading pharmaceutical firm specializing in neuroscience and mental health treatments. Its schizophrenia portfolio includes Zyprexa (olanzapine), widely used for symptom control. The company’s continued CNS research supports innovation in cognitive impairment schizophrenia management and broader psychiatric treatment advancements globally.
Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd., headquartered in Osaka, Japan, and established in 1897, focuses on central nervous system and psychiatric disorders. Its schizophrenia portfolio includes Risperdal, used for symptom stabilization and functional improvement. The company continues advancing CNS research supporting therapies targeting negative symptoms, strengthening long-term psychiatric care solutions in the markets.
Other key players in the market are Johnson & Johnson Services, Inc., Pfizer, Inc., Allergan, Inc., Alkermes plc, Vanda Pharmaceuticals Inc., and H. Lundbeck A/S.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Key Questions Answered in the Schizophrenia Market Report
- What was the schizophrenia market value in 2025?
- What is the schizophrenia market forecast outlook for 2026-2035?
- What major factors aid the demand for schizophrenia market?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market’s major drivers, opportunities, and restraints?
- What are the major schizophrenia market trends?
- Which type is expected to dominate the market segment?
- Which drug class is expected to dominate the market segment?
- Which route of administration is expected to dominate the market segment?
- Which end user is expected to dominate the market segment?
- Which distribution channel is expected to dominate the market segment?
- Who are the key players in the schizophrenia market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Pricing Plans
Upto 15% Off
USD
-
$5499 $4949
-
$3299 $2969
-
$6999 $5949
-
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
